(Q37272524)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18800065%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

review article

1 reference

title

Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18800065%20AND%20SRC:MED&resulttype=core&format=json

protein-protein interaction

14 January 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18800065%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Levi L Blazer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18800065%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

English

0 references

publication date

17 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18800065%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

published in

Neuropsychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18800065%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18800065%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18800065%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

126-141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18800065%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/npp.2008.151

14 January 2020

exact match

0 references

cites work

On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

Integration of NMR and high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

Emerging roles of Dlg-like PDZ proteins in the organization of the NMDA-type glutamatergic synapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Alzhemed: a potential treatment for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Small-molecule inhibitors of protein-protein interactions: progressing towards the dream

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

The GTPase-activating protein RGS4 stabilizes the transition state for nucleotide hydrolysis

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Drosophila as a model for human neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Anatomy of hot spots in protein interfaces

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Differential targeting of Gbetagamma-subunit signaling with small molecules

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Integrated treatment approach improves cognitive function in demented and clinically depressed patients

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Psychostimulants, madness, memory... and RGS proteins?

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

A small molecule targeting the multifactorial nature of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Multi-target-directed ligands to combat neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

High-throughput screen for small molecule inhibitors of Mint1-PDZ domains

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Linkage disequilibrium patterns and functional analysis of RGS4 polymorphisms in relation to schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Association and linkage analyses of RGS4 polymorphisms in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Supramolecular signalling complexes in the nervous system.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

KFC Server: interactive forecasting of protein interaction hot spots.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Part I: parkin-associated proteins and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Neuroimmunology of Alzheimer's disease: a conference report

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Profile of RGS expression in single rat atrial myocytes

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Neuropathology of synuclein aggregates

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Epidemiologic studies of environmental exposures in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

New genetic insights into Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

The binding interface database (BID): a compilation of amino acid hot spots in protein interfaces

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Small molecule inhibitors of p53/MDM2 interaction

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Rational design of a nonpeptide general chemical scaffold for reversible inhibition of PDZ domain interactions.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

A selective irreversible inhibitor targeting a PDZ protein interaction domain.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Design of a selective chemical probe for class I PDZ domains

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

PDZ domains in synapse assembly and signalling

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

RGSZ1 and GAIP regulate mu- but not delta-opioid receptors in mouse CNS: role in tachyphylaxis and acute tolerance

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Chemical control over protein-protein interactions: beyond inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Regional distribution of regulators of G-protein signaling (RGS) 1, 2, 13, 14, 16, and GAIP messenger ribonucleic acids by in situ hybridization in rat brain.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

RGS4 polymorphisms and risk of schizophrenia: an association study in Han Chinese plus meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Selective inhibition of alpha1A-adrenergic receptor signaling by RGS2 association with the receptor third intracellular loop

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Beta strand peptidomimetics as potent PDZ domain ligands

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Cellular regulation of RGS proteins: modulators and integrators of G protein signaling

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Resistance to diet-induced obesity and improved insulin sensitivity in mice with a regulator of G protein signaling-insensitive G184S Gnai2 allele.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gnai2 allele

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

RGS4 is not a susceptibility gene for schizophrenia in Japanese: association study in a large case-control population

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Phosphatidylinositol 3,4,5-trisphosphate and Ca2+/calmodulin competitively bind to the regulators of G-protein-signalling (RGS) domain of RGS4 and reciprocally regulate its action

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

In vivo interaction between RGS4 and calmodulin visualized with FRET techniques: possible involvement of lipid raft

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Structure-based design, synthesis, and activity of peptide inhibitors of RGS4 GAP activity

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Signal transduction molecules at the glutamatergic postsynaptic membrane

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

The emerging role of PDZ adapter proteins for regulation of intestinal ion transport

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

A point mutation in Galphao and Galphai1 blocks interaction with regulator of G protein signaling proteins

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Molecular mechanisms of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

A century-old debate on protein aggregation and neurodegeneration enters the clinic

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Targeting MDM2 and MDMX in retinoblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of G-protein signaling 4 (RGS4)

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Association study of the G-protein signaling 4 (RGS4) and proline dehydrogenase (PRODH) genes with schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Confirming RGS4 as a susceptibility gene for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Neuronal survival and cell death signaling pathways.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Regulation of transducin GTPase activity by human retinal RGS.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Activation of transducin guanosine triphosphatase by two proteins of the RGS family

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Regulators of G protein signaling (RGS proteins): novel central nervous system drug targets

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Regulators of G-protein signalling as new central nervous system drug targets.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Alpha-synuclein: normal function and role in neurodegenerative diseases.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

RGS17/RGSZ2 and the RZ/A family of regulators of G-protein signaling.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Molecular mechanisms of glutamate receptor clustering at excitatory synapses

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Emerging classes of protein-protein interaction inhibitors and new tools for their development

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1)

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Signalling pathways mediating inflammatory responses in brain ischaemia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Ca2+/Calmodulin reverses phosphatidylinositol 3,4, 5-trisphosphate-dependent inhibition of regulators of G protein-signaling GTPase-activating protein activity

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Cadherins and the formation of neural circuitry in the vertebrate CNS.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Multi-tasking RGS proteins in the heart: the next therapeutic target?

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Mechanism of action and structural requirements of constrained peptide inhibitors of RGS proteins

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Novel peptide ligands of RGS4 from a focused one-bead, one-compound library

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Rational approach to discover multipotent anti-Alzheimer drugs.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Spinophilin: from partners to functions

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Diagnosis and treatment of Parkinson disease: molecules to medicine

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Evidence that a protein-protein interaction 'hot spot' on heterotrimeric G protein betagamma subunits is used for recognition of a subclass of effectors

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Identification of a specific inhibitor of the dishevelled PDZ domain

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

NHERF: targeting and trafficking membrane proteins

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

MultiBind and MAPPIS: webservers for multiple alignment of protein 3D-binding sites and their interactions

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Structural determinants for regulation of phosphodiesterase by a G protein at 2.0 A

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

G protein betagamma subunits as targets for small molecule therapeutic development

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

An association study of RGS4 polymorphisms with clinical phenotypes of schizophrenia in a Chinese population

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Gene copy number variation in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Structure of RGS4 bound to AlF4--activated G(i alpha1): stabilization of the transition state for GTP hydrolysis

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Evaluating chick Galpha-interacting protein selectivity

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Tyrosine kinase inhibitors: from rational design to clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Regulators of G protein signaling & drugs of abuse.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Identification of peptides that inhibit regulator of G protein signaling 4 function

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

18 Systematic mutational analyses of protein-protein interfaces

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Between a rock and a hard place?

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

The retinal specific protein RGS-r competes with the gamma subunit of cGMP phosphodiesterase for the alpha subunit of transducin and facilitates signal termination

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Support for RGS4 as a susceptibility gene for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

Structural Basis for the Selectivity of the RGS Protein, GAIP, for G i Family Members: IDENTIFICATION OF A SINGLE AMINO ACID DETERMINANT FOR SELECTIVE INTERACTION OF G i SUBUNITS WITH GAIP

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

https://api.crossref.org/works/10.1038%2FNPP.2008.151

1 reference

7 January 2021

Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioids

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) protien-mediated kinetic scaffolding.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021

The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.151

7 January 2021